Share-based compensation
expenses 7,013 3,827
-------------------- -------------------
Adjusted operating loss (24,063) (34,485)
-------------------- -------------------
Net loss (29,822) (38,907)
Share-based compensation
expenses 7,013 3,827
Income tax (benefits)/expenses (5,205) 119
Interest income (2,264) (2,901)
Interest expense 5,314 4,105
Adjusted EBIT (24,964) (33,757)
-------------------- -------------------
Net loss attributable to Zepp
Health Corporation (29,741) (38,857)
Share-based compensation
expenses 7,013 3,827
-------------------- -------------------
Adjusted net loss attributable
to Zepp Health Corporation([)
(2]) (22,728) (35,030)
==================== ===================
Adjusted net loss per share
attributable to Zepp Health
Corporation
Adjusted basic loss per
ordinary share (0.09) (0.14)
Adjusted diluted loss per
ordinary share (0.09) (0.14)
Adjusted net loss per ADS (16
ordinary shares equal to
1 ADS)([3])
ADS -- basic (1.49) (2.16)
ADS -- diluted (1.49) (2.16)
Weighted average number of
shares used in computing
adjusted net loss per share
Ordinary share -- basic 243,679,883 259,433,512
Ordinary share -- diluted 243,679,883 259,433,512
Share-based compensation
expenses included are
follows:
Selling and marketing 497 368
General and administrative 3,154 1,812
Research and development 3,362 1,647
-------------------- -------------------
Total 7,013 3,827
-------------------- -------------------
View original content:https://www.prnewswire.com/news-releases/zepp-health-corporation-reports-third-quarter-2024-unaudited-financial-results-302308549.html
SOURCE Zepp Health Corp.
(END) Dow Jones Newswires
November 18, 2024 20:00 ET (01:00 GMT)
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。